After adjusting for age, race, education, alcohol consumption, exercise, body mass index and smoking, silymarin users showed significantly less fatigue, nausea, liver
pain, anorexia, muscle and
joint pain, and improvements in general health over non-users.
Confirming that silymarin has little direct effect on the Hepatitis C virus, the qualitative values generally used to evaluate virus severity were similar in silymarin users and non-users.